Alumis (ALMS) and ACELYRIN (SLRN) have announced an amended merger agreement with revised terms. Under the new agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share, resulting in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning 48% of the combined company.
The merger aims to create a leading clinical-stage immunology company with a diversified portfolio. With a pro forma cash position of approximately $737 million as of December 31, 2024, the combined company expects to fund operations into 2027, supporting multiple planned clinical trial readouts.
The transaction, supported by stockholders representing 62% of Alumis voting common stock and 24% of ACELYRIN common stock, is expected to close in Q2 2025. Both companies will hold Special Meeting of Stockholders on May 13, 2025, with a record date of April 1, 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.